Golden State Equity Partners Raises Holdings in Eli Lilly and Company $LLY

Key Points

• Golden State Equity Partners increased its holdings in Eli Lilly by 23.1% during Q2, acquiring an additional 582 shares and bringing its total to 3,104 shares valued at approximately $2.42 million.
• Eli Lilly reported earnings of $6.31 per share, exceeding expectations, with revenue of $15.56 billion for the quarter, representing a 37.6% increase year-over-year.
• Insider trading activity reveals significant purchases by executives, including EVP Daniel Skovronsky, who bought 1,000 shares at an average cost of $634.40 each, totaling over $634,000.

Golden State Equity Partners increased its position in Eli Lilly and Company (NYSE:LLY - Free Report) by 23.1% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 3,104 shares of the company's stock after acquiring an additional 582 shares during the period. Golden State Equity Partners' holdings in Eli Lilly and Company were worth $2,420,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also modified their holdings of the company. Duquesne Family Office LLC grew its holdings in shares of Eli Lilly and Company by 52.5% in the 1st quarter. Duquesne Family Office LLC now owns 94,830 shares of the company's stock worth $78,321,000 after acquiring an additional 32,640 shares during the period. Corient IA LLC acquired a new stake in shares of Eli Lilly and Company in the 1st quarter worth approximately $570,000. LS Investment Advisors LLC grew its holdings in shares of Eli Lilly and Company by 1.7% in the 1st quarter. LS Investment Advisors LLC now owns 2,340 shares of the company's stock worth $1,933,000 after acquiring an additional 40 shares during the period. Cutter Capital Management LP acquired a new stake in shares of Eli Lilly and Company in the 1st quarter worth approximately $14,866,000. Finally, Prism Advisors Inc. acquired a new stake in shares of Eli Lilly and Company in the 1st quarter worth approximately $207,000. Institutional investors and hedge funds own 82.53% of the company's stock.

Eli Lilly and Company Trading Up 0.4%

Shares of LLY opened at $755.32 on Tuesday. The company has a current ratio of 1.28, a quick ratio of 1.00 and a debt-to-equity ratio of 1.86. The firm has a market capitalization of $714.88 billion, a P/E ratio of 49.37, a price-to-earnings-growth ratio of 1.05 and a beta of 0.47. The stock's fifty day simple moving average is $737.49 and its 200 day simple moving average is $769.01. Eli Lilly and Company has a twelve month low of $623.78 and a twelve month high of $939.30.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last issued its earnings results on Thursday, August 7th. The company reported $6.31 earnings per share for the quarter, topping the consensus estimate of $5.59 by $0.72. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The business had revenue of $15.56 billion for the quarter, compared to analyst estimates of $14.40 billion. During the same period last year, the company posted $3.92 EPS. The business's quarterly revenue was up 37.6% on a year-over-year basis. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. On average, equities research analysts forecast that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Insider Buying and Selling

In related news, EVP Daniel Skovronsky acquired 1,000 shares of the business's stock in a transaction on Tuesday, August 12th. The shares were bought at an average cost of $634.40 per share, with a total value of $634,400.00. Following the completion of the transaction, the executive vice president directly owned 137,660 shares of the company's stock, valued at $87,331,504. This trade represents a 0.73% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director J Erik Fyrwald acquired 1,565 shares of the business's stock in a transaction on Tuesday, August 12th. The stock was bought at an average cost of $642.33 per share, for a total transaction of $1,005,246.45. Following the completion of the transaction, the director directly owned 74,578 shares of the company's stock, valued at $47,903,686.74. This trade represents a 2.14% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders bought a total of 4,514 shares of company stock valued at $2,894,841 over the last ninety days. Insiders own 0.14% of the company's stock.

Wall Street Analyst Weigh In

A number of equities research analysts have commented on LLY shares. Wall Street Zen cut Eli Lilly and Company from a "strong-buy" rating to a "buy" rating in a report on Saturday. UBS Group lowered their target price on Eli Lilly and Company from $1,050.00 to $895.00 and set a "buy" rating on the stock in a report on Friday, August 8th. Daiwa America cut Eli Lilly and Company from a "strong-buy" rating to a "hold" rating in a report on Sunday, August 17th. Morgan Stanley reiterated an "overweight" rating and set a $1,135.00 target price (up previously from $1,133.00) on shares of Eli Lilly and Company in a report on Thursday, July 10th. Finally, DZ Bank upgraded Eli Lilly and Company from a "hold" rating to a "strong-buy" rating in a report on Thursday, August 14th. One research analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and nine have issued a Hold rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $939.61.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.